Preoperative tumor progression significantly predicts early mortality in patients undergoing cytoreductive hepatectomy for neuroendocrine tumor liver metastases.

• 47% of short-term survivors had preoperative progression compared to 16.6% of long-term survivors (p < 0.001).
• Patients with pancreatic neuroendocrine tumors and progression faced a median overall survival of just 1.8 years (p = 0.042).

Incorporating tumor progression metrics into preoperative evaluations can refine surgical decision-making and improve patient outcomes.

• Tumor growth over 20% and weekly growth over 1.04% were strongly linked to early mortality (p < 0.001).